These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26289557)

  • 21. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
    Mueller T; Gegenhuber A; Haltmayer M
    Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
    [No Abstract]   [Full Text] [Related]  

  • 22. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
    Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
    Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
    J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine.
    Cavusoglu Y; Tek M; Birdane A; Ata N; Demirustu C; Gorenek B; Unalir A; Timuralp B
    Int J Cardiol; 2008 Jul; 127(3):e188-91. PubMed ID: 17884200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients.
    Parissis JT; Papadopoulos C; Nikolaou M; Bistola V; Farmakis D; Paraskevaidis I; Filippatos G; Kremastinos D
    Cardiovasc Drugs Ther; 2007 Aug; 21(4):263-8. PubMed ID: 17610056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
    Flevari P; Parissis JT; Leftheriotis D; Panou F; Kourea K; Kremastinos DT
    Am J Cardiol; 2006 Dec; 98(12):1641-5. PubMed ID: 17145226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
    Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
    JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
    Hou ZQ; Sun ZX; Su CY; Tan H; Zhong X; Hu B; Zhou Y; Shang DY
    Cardiovasc Ther; 2013 Apr; 31(2):108-14. PubMed ID: 23490237
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
    Farmakis D; Parissis JT; Bistola V; Paraskevaidis IA; Iliodromitis EK; Filippatos G; Kremastinos DT
    Int J Cardiol; 2010 Feb; 139(1):75-9. PubMed ID: 18973957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
    Milwidsky A; Frydman S; Laufer-Perl M; Sadeh B; Sapir O; Granot Y; Hochstadt A; Korotetski L; Ketchker L; Topilsky Y; Banai S; Havakuk O
    ESC Heart Fail; 2022 Apr; 9(2):1487-1491. PubMed ID: 35083882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
    Paraskevaidis IA; Bistola V; Ikonomidis I; Parissis JT; Papadopoulos C; Filippatos G; Kremastinos DT
    Am J Cardiol; 2008 Nov; 102(9):1225-9. PubMed ID: 18940297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].
    Prijić S; Rakić S; Nikolić L; Jovicić B; Stajević M; Vukomanović V; Kosutić J
    Vojnosanit Pregl; 2011 Nov; 68(11):979-84. PubMed ID: 22191317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Safety and efficacy of the early administration of levosimendan in patients with acute non-ST-segment elevation myocardial infarction and elevated NT-proBNP levels: An Early Management Strategy of Acute Heart Failure (EMS-AHF)].
    Xu F; Bian Y; Zhang GQ; Gao LY; Liu YF; Liu TX; Li G; Song RX; Su LJ; Zhou YJ; Cui JY; Yan XL; Guo FM; Zhang HY; Li QH; Zhao M; Ma LK; You BA; Wang G; Kong L; Ma JL; Zhou XF; Chang ZL; Tang ZY; Yu DY; Cheng K; Xue L; Li X; Pang JJ; Wang JL; Zhang HT; Yu XZ; Chen YG
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):374-383. PubMed ID: 37032132
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis].
    Xu ZD; He WX; Zhao YF; Xia SX; He B; Yang T; Cao DX; Peng SL; Li J; Cao MH
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2027-9. PubMed ID: 19861257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.